CN108578556A - 一种降血糖降血脂的保健品及其制备方法 - Google Patents
一种降血糖降血脂的保健品及其制备方法 Download PDFInfo
- Publication number
- CN108578556A CN108578556A CN201810801655.7A CN201810801655A CN108578556A CN 108578556 A CN108578556 A CN 108578556A CN 201810801655 A CN201810801655 A CN 201810801655A CN 108578556 A CN108578556 A CN 108578556A
- Authority
- CN
- China
- Prior art keywords
- parts
- health products
- raw material
- blood sugar
- reducing blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 70
- 210000004369 blood Anatomy 0.000 title claims abstract description 69
- 230000036541 health Effects 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 40
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 32
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 31
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 23
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 23
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 8
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 238000011049 filling Methods 0.000 claims abstract description 6
- 235000020985 whole grains Nutrition 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 244000291564 Allium cepa Species 0.000 claims abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 244000302512 Momordica charantia Species 0.000 claims description 10
- 235000009811 Momordica charantia Nutrition 0.000 claims description 9
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims description 9
- 235000018365 Momordica dioica Nutrition 0.000 claims description 9
- 235000019441 ethanol Nutrition 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 17
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 7
- 230000003862 health status Effects 0.000 abstract description 2
- 241000234282 Allium Species 0.000 description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 13
- 235000011201 Ginkgo Nutrition 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 240000000249 Morus alba Species 0.000 description 7
- 235000008708 Morus alba Nutrition 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 229930003944 flavone Natural products 0.000 description 6
- 235000011949 flavones Nutrition 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000000291 postprandial effect Effects 0.000 description 6
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 229910001369 Brass Inorganic materials 0.000 description 4
- 239000010951 brass Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- -1 Phenylpropanoid Glycosides phenols Chemical class 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229930184727 ginkgolide Natural products 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 230000004203 pancreatic function Effects 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- PFRGXCVKLLPLIP-UHFFFAOYSA-N diallyl disulfide Chemical compound C=CCSSCC=C PFRGXCVKLLPLIP-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种降血糖降血脂的保健品及其制备方法，该保健品包括以下原料：洋葱冻干粉290‑300份，苦瓜提取物82‑88份，银杏叶提取物20‑28份，桑叶提取物90‑96份，硬脂酸镁4‑7份。该保健品的制备方法，包括以下步骤：步骤1，对洋葱冻干粉、苦瓜提取物、银杏叶提取物、桑叶提取物分别进行粉碎，过80‑100目筛网，得原料细粉；步骤2，将原料细粉混合20‑30min，湿化处理得混合料，将混合料过20目筛网得湿颗粒；步骤3，将湿颗粒沸腾干燥后，加入硬脂酸镁，混匀，过18目筛网整粒得干颗粒，将干颗粒灌装形成胶囊，得降血糖降血脂的保健品。本发明所得保健品，可显著改善糖尿病和高血脂人群的健康状况，对于普通人群也可起到预防糖尿病和高血脂的疾病的目的。
Description
技术领域
本发明涉及保健品技术领域，尤其涉及一种降血糖降血脂的保健品及其制备方法。
背景技术
高血脂的严格定义为血脂紊乱或血脂异常，是指人体内血清脂质的浓度水平超出了正常范围，包括血清总胆固醇(TC)水平升高，血清甘油三脂(TG)水平升高，血清高密度脂蛋白胆固醇(HDLE)水平异常减低。是心脑血管疾病的主要危险因素之一。它的直接损害是加速全身动脉粥样硬化，因为全身的重要器官都要依靠动脉供血、供氧，一旦动脉被粥样斑块堵塞，就会导致严重后果。近年来高血脂患者有向年轻化发展趋势。一般情况下，高血脂的发病率随着年龄的增加有增高的趋势，患者以45-60岁的成年人为主，其中，中青年的男性较多，中年以后的女性患者也不少，就目前临床发现，年轻人也有明显增加的趋势，另外，肥胖的人也较易患上高血脂。
糖尿病是以机体胰岛素分泌绝对或相对不足而引起血糖异常升高的疾病，是一种内脏代谢功能紊乱症，糖尿病的发生主要是微循环不良、胰腺功能失调和胰岛素抵抗等问题。其特征性表现为高血糖和糖尿，同时也包括蛋白质、脂肪、水电解质等的紊乱。糖尿病在传统医学中称为消渴病，临床认为消渴病的病理在于阴津亏耗，燥热偏盛，阴虚为本，燥热为标。
现阶段，随着人们生活水平的不断提高，高脂血症和糖尿病的发病率呈明显上升趋势，已经成为现在的流行病。高脂血症的主要危险是导致动脉硬化，是致死性疾病如冠心病、脑卒中、心肌梗死的重要危险因素，也是加重高血压、糖尿病、脂肪肝、肝硬化、胰腺炎等疾病的因素之一。高脂血症对身体的损害是隐匿、逐渐、长期和全身性的，多数人需长期用药治疗。但是如果长期服用调血脂西药，又会因药物的副作用而使患者的身体健康受到损害。
发明内容
针对现有技术中存在的问题，本发明的目的在于提供一种降血糖降血脂的保健品，该保健品具有辅助降血糖降血脂的作用，长期食用，可改善糖尿病和高血脂人群的健康状况，同时对糖尿病和高血脂有一定的预防作用。
本发明的另一个目的是提供一种降血糖降血脂的保健品的制备方法，该制备方法易于工业化生产。
为达到上述目的，本发明采用以下技术方案予以解决。
一种降血糖降血脂的保健品，包括以下原料：洋葱冻干粉、苦瓜提取物、银杏叶提取物、桑叶提取物和硬脂酸镁。
优选的，所述原料重量份为：洋葱冻干粉290-300份，苦瓜提取物82-88份，银杏叶提取物20-28份，桑叶提取物90-96份，硬脂酸镁4-7份。
进一步优选的，所述原料重量份为洋葱冻干粉295份，苦瓜提取物85份，银杏叶提取物25份，桑叶提取物95份，硬脂酸镁5份。
本发明提供的一种降血糖降血脂的保健品的制备方法，包括以下步骤：
步骤1，备料：对洋葱冻干粉、苦瓜冻干粉、银杏叶提取物、桑叶提取物分别进行粉碎，过80-100目筛网，得原料细粉；
步骤2，混合制粒：将原料细粉搅拌混合20-30min，湿化处理，得混合料，将混合料过20-25目筛网，得湿颗粒；
步骤3，干燥整粒：将湿颗粒沸腾干燥后，加入硬脂酸镁，搅拌混合均匀，过15-18目筛网，整粒，得干颗粒；将干颗粒灌装形成胶囊，得降血糖降血脂的保健品。
优选的，步骤2中，所述湿化处理为：加入乙醇，搅拌混合。
进一步优选的，所述湿化处理为：加入6％-8％原料细粉重量的体积分数为65％-75％乙醇，搅拌混合20-40min。
优选的，步骤3中，所述沸腾干燥为在55-65℃条件下干燥1-2h。
本发明中的各原料的功效如下：
洋葱：洋葱为百合科植物洋葱的鳞茎，具强烈的香气；近代医学研究发现，洋葱含有硫化物、类黄酮、苯丙素酚类、甾体皂苷类、含氯化合物、***素类和多糖等多种化学成分，具有消炎抑菌、防癌抗癌、利尿止泻，洋葱水溶液降血糖、降血脂、降胆固醇、降血压、抗血小板凝聚、预防心脑血管病、抗氧化、美容等多种药理作用，可能与洋葱中所含的二烯丙基化物，烯丙基二硫化物，含硫氨基酸等有关，此外，洋葱中富含纤维素，可阻碍食物中胆固醇和甘油三酯的吸收，进而影响血液中胆固醇的含量。
大量研究证实，洋葱提取物具有降血糖的作用，其作用机理为：洋葱中的含硫氨基酸和二硫化物可以消耗胆固醇和脂类合成所必需的NADPH和含-SH的酶，从而防止胰岛素被破坏，起到降血糖的作用。
苦瓜：苦瓜为葫芦科植物苦瓜的果实，性味苦、寒，可清暑涤热，明目，解毒。治热病烦渴引饮，中暑，痢疾，赤眼疼痛，痈肿丹毒，恶疮。作为食用蔬菜，资源广泛，方便易得。苦瓜中有葫芦索烷型、齐墩果烷型皂苷，以及甾醇及其苷类、生物碱类等。近年来的药理研究表明，苦瓜具有显著的药理活性，尤其是降糖、抗肿瘤和抗病毒方面的活性值得深入研究。
银杏叶：归心，肺经，敛肺，平喘，活血化瘀。银杏叶的药理研究和利用主要集中在银杏叶内脂、银杏叶多糖和银杏叶黄铜等。尤其是银杏叶提取物及其各种制剂。银杏叶提取物的有效成分主要有银杏黄铜、白果内脂和银杏内酯等，其中，银杏黄铜是一种自由基清除剂，可有效降低血清胆固醇量，升高血清磷脂量，改善血清中胆固醇与磷脂的比例；白果内脂可增强细胞色素酶的表达；银杏内酯降低脑毛细血管通透性，改善血液流变学指数，具有明显的脑保护作用。
桑叶：桑叶为桑科植物桑的叶，性苦，甘，寒，可祛风清热，凉血明目。治风温发热，头痛，目赤，口渴，肺热咳嗽，风痹，瘾疹，下肢象皮肿。桑叶中含有丰富的桑叶黄酮，同时含有丰富的胡萝卜素、槲皮素、维生素C等。桑叶黄酮通过抗氧化机制清除自由基，保持胰岛细胞的结构完整，维持其正常生理功能，从而降低糖尿病患者的血糖水平。阻止并发症发生。现代研究发现，桑叶具有抑制血糖值上升、降血压的作用，同时可降低血清总胆固醇并减少其在血管内壁的沉积。
与现有技术相比，本发明具有如下有益效果：
(1)本发明的降血糖降血脂的保健品中的洋葱冻干粉和苦瓜提取物均取自食物，而银杏叶提取物和桑叶提取物为两味中药，均可保证食用的安全性，原料易得，成本低廉，打破市售保健品价格昂贵的局面。
(2)本发明将洋葱冻干粉、苦瓜提取物、银杏叶提取物和桑叶提取物进行合理配伍，不仅发挥出各原料本身的药用效果，同时，由于银杏叶提取物具有改善人体血液流变性的功效，而银杏叶提取物中的内酯和黄酮与洋葱冻干粉、苦瓜提取物和桑叶提取物相互协同作用，能够活化血液、扩张血管、抗血栓，增加血流量，促进血液循环，尤其对改善血液微循环效果显著，而微血管病变是糖尿病的主要并发症之一，是其他各种并发症的病理基础，因此，通过将银杏叶提取物与洋葱冻干粉、苦瓜提取物和桑叶提取物进行合理配伍，可显著改善人体血液微循环，使胰脏功能逐渐恢复，血脂浓度逐渐降低，进而达到显著的降血糖降血脂的作用。长期服用本发明的保健品，可显著改善高血脂和高血糖人群的健康状况，对于普通人群也可起到预防高血脂和高血糖疾病的目的。
(3)本发明选用胶囊剂型，可提高药物稳定性、掩盖药物不适的苦味，使本品在胃肠道内分散快、吸收好，同时易于储存。
具体实施方式
下面将结合实施例对本发明的实施方案进行详细描述，但是本领域的技术人员将会理解，下列实施例仅用于说明本发明，而不应视为限制本发明的范围。
实施例1
称取290g洋葱冻干粉、88g苦瓜冻干粉、28g银杏叶提取物、90g桑叶提取物，分别用粉碎机粉碎后，分别过80目筛网，得原料细粉：将原料细粉搅拌混合20min，加入体积分数65％乙醇继续混合20min，得混合料，将混合料过20目筛网得湿颗粒；将湿颗粒55℃烘干2h后，加入4g硬脂酸镁，搅拌混合20min后，过18目筛网得干颗粒，将干颗粒灌装形成胶囊，得降血糖降血脂的保健品，装量为0.5g/粒。
实施例2
称取300g洋葱冻干粉、82g苦瓜冻干粉、20g银杏叶提取物、96g桑叶提取物，分别用粉碎机粉碎后，分别过90目筛网，得原料细粉：将原料细粉搅拌混合25min，加入体积分数70％乙醇继续混合25min，得混合料，将混合料过20目筛网得湿颗粒；将湿颗粒60℃烘干1.5h后，加入7g硬脂酸镁，搅拌混合均30min后，过18目筛网得干颗粒，将干颗粒灌装形成胶囊，得降血糖降血脂的保健品，装量为0.5g/粒。
实施例3
称取295g洋葱冻干粉、85g苦瓜冻干粉、25g银杏叶提取物、95g桑叶提取物，分别用粉碎机粉碎后，分别过100目筛网，得原料细粉：将原料细粉搅拌混合30min，加入体积分数75％乙醇继续混合30min，得混合料，将混合料过20目筛网得湿颗粒；将湿颗粒65℃烘干1h后，加入5g硬脂酸镁，搅拌混合40min后，过18目筛网得干颗粒，将干颗粒灌装形成胶囊，得降血糖降血脂的保健品，装量为0.5g/粒。
本发明各实施例所得降血糖降血脂的保健品中，洋葱冻干粉、苦瓜提取物、银杏叶提取物、桑叶提取物进行合理配伍，不仅发挥各原料本身的药用效果，且通过银杏叶提取物与洋葱冻干粉、苦瓜提取物、桑叶提取物进行合理配伍，使各原料的降血糖降血脂的效果显著提高。具体地，银杏叶提取物中的银杏黄铜-糖疳具有强大的抗氧化与清除自由基能力，可有效延缓机体衰老，降低恶性肿瘤发病率，同时，有效提升本品中的标志性成分总黄酮量。此外，银杏叶提取物中的银杏内酯和黄铜可与洋葱冻干粉、苦瓜提取物、桑叶提取物相互协同作用，改善人体血液微循环，使胰脏功能逐渐恢复，进而缓解糖尿病引起的并发症，使该保健品的降血糖降血脂功效显著提高。
本发明的标志性成分为总黄酮和总皂苷，其中，总黄酮≥1.3g/100g，总皂苷≥0.7g/100g。
本发明保健品的生产环境为10万级洁净生产区，本发明中使用的方法，若无特殊说明，均为常规方法。典型病例如下：
王某某，男，50岁，新疆阿克苏地区沙雅县人。有两年糖尿病史，平时会有多饮、多尿、多食、疲乏、皮肤干燥等症状，连续服用本发明实施例1所得保健品90天后，服用方法为：每天两次，每次2粒，血糖由原来的空腹为7.8mmol/L，餐后2小时为11.9mmol/L，下降到血糖空腹为6.0mmol/L，餐后2小时为9.5mmol/L；同时，以上身体不适的症状也有明显改善，整个人精神状态良好，随访一年，饮食趋于正常，身体状况良好。
张某某，女，61岁，新疆阿克苏地区沙雅县人，有三年糖尿病史并伴有高血脂，平时会有多尿、多食、头晕目眩、头痛、胸闷、气短、心慌、胸痛、乏力等症状，连续服用本发明实施例2所得保健品60天后，服用方法为：每天两次，每次1粒，血糖由原来的空腹为8.1mmol/L，餐后2小时为12.0mmol/L，下降到血糖空腹为6.5mmol/L，餐后2小时为9.5mmol/L；同时，以上身体不适的症状也有明显改善，随访一年身体状态好转，饮食趋于正常。
李某某，男，70岁，陕西省三原县人，有五年糖尿病史并伴有高血脂，平时会有头晕目眩、头痛、胸闷、气短、心慌、胸痛、乏力等症状，偶尔会出现口角歪斜、肢体麻木等症状，连续服用本发明实施例3所得保健品120天后，服用方法为：每天三次，每次2粒，血糖由原来的空腹为9.0mmol/L，餐后2小时为12.5mmol/L，下降到血糖空腹为7.2mmol/L，餐后2小时为10.9mmol/L；同时，以上身体不适的症状也有明显改善，随访一年，身体状态逐渐好转且口角歪斜和肢体麻木的症状没有再出现。
虽然，本说明书中已经用一般性说明及具体实施方案对本发明作了详尽的描述，但在本发明基础上，可以对之作一些修改或改进，这对本领域技术人员而言是显而易见的。因此，在不偏离本发明精神的基础上所做的这些修改或改进，均属于本发明要求保护的范围。
Claims (7)
1.一种降血糖降血脂的保健品，其特征在于，包括以下原料：洋葱冻干粉、苦瓜提取物、银杏叶提取物、桑叶提取物和硬脂酸镁。
2.根据权利要求1所述的降血糖降血脂的保健品，其特征在于，所述原料的重量份为：洋葱冻干粉290-300份，苦瓜提取物82-88份，银杏叶提取物20-28份，桑叶提取物90-96份，硬脂酸镁4-7份。
3.根据权利要求1所述的降血糖降血脂的保健品，其特征在于，所述原料的重量份为洋葱冻干粉295份，苦瓜提取物85份，银杏叶提取物25份，桑叶提取物95份，硬脂酸镁5份。
4.一种降血糖降血脂的保健品的制备方法，其特征在于，包括以下步骤：
步骤1，备料：对洋葱冻干粉、苦瓜冻干粉、银杏叶提取物、桑叶提取物分别进行粉碎，过80-100目筛网，得原料细粉；
步骤2，混合制粒：将原料细粉搅拌混合20-30min，湿化处理，得混合料，将混合料过20-25目筛网，得湿颗粒；
步骤3，干燥整粒：将湿颗粒沸腾干燥后，加入硬脂酸镁，搅拌混合均匀，过15-18目筛网，整粒，得干颗粒；将干颗粒灌装形成胶囊，得降血糖降血脂的保健品。
5.根据权利要求4所述的降血糖降血脂的保健品的制备方法，其特征在于，步骤2中，所述湿化处理为：加入乙醇，搅拌混合。
6.根据权利要求5所述的降血糖降血脂的保健品的制备方法，其特征在于，所述湿化处理为：加入6％-8％原料细粉重量的体积分数为65％-75％乙醇，搅拌混合20-40min。
7.根据权利要求4所述的降血糖降血脂的保健品的制备方法，其特征在于，步骤3中，所述沸腾干燥为在55-65℃条件下干燥1-2h。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810801655.7A CN108578556A (zh) | 2018-07-20 | 2018-07-20 | 一种降血糖降血脂的保健品及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810801655.7A CN108578556A (zh) | 2018-07-20 | 2018-07-20 | 一种降血糖降血脂的保健品及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108578556A true CN108578556A (zh) | 2018-09-28 |
Family
ID=63618689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810801655.7A Pending CN108578556A (zh) | 2018-07-20 | 2018-07-20 | 一种降血糖降血脂的保健品及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108578556A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109362940A (zh) * | 2018-10-12 | 2019-02-22 | 常同喜 | 一种海洋胶原肽及降糖制剂的制备方法 |
| CN112121114A (zh) * | 2020-11-04 | 2020-12-25 | 新疆华圣元医药科技有限公司 | 一种具有辅助降血脂作用的药物组合物及其制剂 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103549417A (zh) * | 2013-10-28 | 2014-02-05 | 新疆昌凯生物科技有限公司 | 一种洋葱苦瓜分散片及其生产工艺 |
-
2018
- 2018-07-20 CN CN201810801655.7A patent/CN108578556A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103549417A (zh) * | 2013-10-28 | 2014-02-05 | 新疆昌凯生物科技有限公司 | 一种洋葱苦瓜分散片及其生产工艺 |
Non-Patent Citations (1)
| Title |
|---|
| 迟玉杰主编: "《保健食品学》", 31 May 2016 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109362940A (zh) * | 2018-10-12 | 2019-02-22 | 常同喜 | 一种海洋胶原肽及降糖制剂的制备方法 |
| CN112121114A (zh) * | 2020-11-04 | 2020-12-25 | 新疆华圣元医药科技有限公司 | 一种具有辅助降血脂作用的药物组合物及其制剂 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105148252A (zh) | 一种复方降糖制剂 | |
| CN109730180A (zh) | 一种降血压、降血脂、降血糖组合物及其制备方法和袋泡茶 | |
| CN103300188A (zh) | 一种苦荞降糖颗粒茶及其制作方法 | |
| CN105707637A (zh) | 一种降糖固体饮料及其制备方法 | |
| CN104431063A (zh) | 防治心脑血管疾病的甜茶功能饮品及其制备方法 | |
| CN108578556A (zh) | 一种降血糖降血脂的保健品及其制备方法 | |
| KR20100109697A (ko) | 체중감량 및 고지혈증 개선 효과가 있는 기능성 조성물 | |
| JP2012131754A (ja) | 抗血栓剤 | |
| CN103637179A (zh) | 一种降血糖、降血脂和改善脂肪肝的食物组合物 | |
| JP2004008215A (ja) | 多機能の健康食品及びその応用 | |
| CN103549417B (zh) | 一种洋葱苦瓜分散片及其生产工艺 | |
| JPWO2005094858A1 (ja) | 抗糖尿病用組成物 | |
| CN102499366B (zh) | 调节血脂和抗疲劳的保健食品 | |
| CN102362936B (zh) | 鸡爪芋提取物的用途及其药品和保健品固体制剂、饮料制剂 | |
| CN100560095C (zh) | 一种含巴旦杏提取物和银杏叶提取物的复方制剂 | |
| CN109549206A (zh) | 一种溶栓及预防心血管疾病的功能性食品及其制备方法 | |
| CN107048395A (zh) | 一种降血压血脂组合物的制备方法 | |
| CN105851352A (zh) | 一种含白茶提取物的有效部位组合物及其制备方法和应用 | |
| CN106260348A (zh) | 一种三叶降压袋泡茶及其制备方法 | |
| CN110477396A (zh) | 一种含竹叶黄酮的多肽食品 | |
| CN104770641A (zh) | 一种银杏叶提取物复合制剂 | |
| JP2006257018A (ja) | 抗肥満剤、医薬品および飲食品 | |
| JP2014043432A (ja) | 桑小枝、桑葉及びオオマツヨイグサをイオン化デキストリンで造粒して顆粒状または成形した錠剤等の製造方法と生理活性 | |
| CN108967757A (zh) | 一种红枣生姜浓浆生产工艺 | |
| RU2773856C1 (ru) | Средство, обладающее гипогликемическим действием, и способ его получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180928 |